MAYNE Pharma has assumed control of the US rights for SUBA-itraconazole in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS, commonly known as Gorlin Syndrome) following the revision of an agreement with HedgePath Pharmaceuticals Inc.
Under the terms of the revised deal Mayne Pharma will pay a 9% royalty on net sales of SUBA-itraconazole for the treatment of BCCNS in the US to HedgePath, as well as committing up to $5 million in funding to HedgePath to progress the development of the product to other cancer indications.
SUBA-itraconazole is a patented formulation with improved absorption and reduced variability compared to conventional itraconazole capsules, which are used to treat fungal infections but also have anti-cancer properties.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Dec 18
